Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kletzel, Morris  [Clear All Filters]
2021
Rossoff J, Jacobsohn D, Kwon S, Kletzel M, Duerst RE, Tse WT, Schneiderman J, Chaudhury S. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatr Blood Cancer. 2021:e29087.
2018
Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LEidenschin, Logan BR, Ahn KWoo, Shaw BE, Kletzel M, Olszewski M, et al. Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biol Blood Marrow Transplant. 2018.
2016
Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, et al. A Phase I Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2016.
2013
Kletzel M. Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation. Rev Bras Hematol Hemoter. 2013;35(5):309-310.